MedTrace Logo

Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management

NCT05184491 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2022-01-11

No results posted yet for this study

Summary

The study will evaluate the eradication rate and tolerability of modified LOAD regimens (three antibiotics and a proton pump inhibitor (lansoprazole)) for management of HP infection in treatment-naive patients as well as patients who failed previous therapies.

Conditions

  • Helicobacter Pylori

Interventions

DRUG

Naïve patients - ACO therapy

Naïve patients will receive classic triple therapy (amoxicillin, clarithromycin and lansoprazole) for 14 days

DRUG

Naïve patients - LNDL therapy

Naïve patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

DRUG

Naïve patients - MNDL therapy

Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

DRUG

Treatment-experienced patients- LNDL therapy

Experienced patients will receive Levofloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

DRUG

Treatment-experienced patients- MNDL therapy

Experienced patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days

Sponsors & Collaborators

  • Future pharmaceutical industries

    collaborator UNKNOWN

  • National Liver Institute, Egypt

    lead OTHER

Principal Investigators

  • Gasser El-Azab, M.D. · National Liver Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2022-02-01
Completion
2022-03-15

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184491 on ClinicalTrials.gov